{"gene":"LYL1","run_date":"2026-04-28T18:30:27","timeline":{"discoveries":[{"year":1989,"finding":"LYL1 encodes a protein containing a helix-loop-helix (HLH) DNA-binding motif, structurally related to Myc, MyoD, and immunoglobulin enhancer-binding proteins, first identified at a chromosomal translocation breakpoint (t(7;19)) in T-ALL.","method":"Molecular cloning, sequence analysis, structural prediction","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — original cloning with structural characterization, foundational paper, 342 citations","pmids":["2752424"],"is_preprint":false},{"year":1996,"finding":"LYL1 forms heterodimeric complexes with E2a proteins (E12 and E47) via their HLH motifs, and these endogenous LYL1-E2a complexes bind a preferred DNA sequence (5'-AACAGATG(T/g)T-3') distinct from the muE2 site recognized by E2a homodimers.","method":"Yeast two-hybrid screen, in vitro binding assay, co-immunoprecipitation, PCR-assisted site selection","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including in vitro reconstitution, Co-IP, and DNA-binding site selection","pmids":["8628307"],"is_preprint":false},{"year":1999,"finding":"LYL1 physically interacts with NF-κB1 p105 (the precursor of p50) via the bHLH motif of LYL1 and the ankyrin-like motifs of p105; ectopic LYL1 expression in T cells significantly reduces NF-κB-dependent transcription.","method":"Yeast two-hybrid screen, in vitro binding assay, co-immunoprecipitation in mammalian cells, transcription reporter assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 — interaction confirmed in vitro and in vivo with functional transcriptional readout","pmids":["10023675"],"is_preprint":false},{"year":2006,"finding":"Lyl1 is required for normal hematopoietic stem cell (HSC) function and B-cell differentiation in vivo; Lyl1-null mice show reduced HSC frequency (LSK, LSK-SP) and severely impaired competitive reconstitution, particularly of B and T lineages.","method":"Knockout mouse model, competitive bone marrow reconstitution assay, flow cytometry, colony-forming assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — clean KO with multiple defined cellular phenotypes and functional reconstitution assays","pmids":["16514064"],"is_preprint":false},{"year":2006,"finding":"Lyl1 promoter activity in hematopoietic progenitor and endothelial cells is driven by conserved binding sites occupied in vivo by GATA-2 and Ets factors (Fli1, Elf1, Erg, PU.1); despite co-regulation with Scl by the same factors, Lyl1 cannot rescue hematopoietic differentiation in Scl-/- ES cells.","method":"Transgenic mouse promoter assay, chromatin immunoprecipitation (ChIP), ES cell differentiation rescue assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 — in vivo ChIP, transgenic promoter analysis, and functional rescue experiments","pmids":["17053063"],"is_preprint":false},{"year":2007,"finding":"LYL1 interacts with CREB1 via the N-terminal domain of LYL1 and the Q2/KID domains of CREB1; these complexes recruit p300/CBP (histone acetyltransferases) independently of CREB1 Ser133 phosphorylation and activate CREB1 target gene promoters including Id1, Id3, cyclin D3, Brca1, Btg2, and Egr1.","method":"Co-immunoprecipitation, luciferase reporter assay, ChIP-chip, domain-mapping mutagenesis","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP with domain mapping, ChIP-chip genome-wide, and functional reporter assays","pmids":["18160048"],"is_preprint":false},{"year":2007,"finding":"Excess LYL1 blocks E2A dimerization and inhibits E2A regulatory activity on the CD4 promoter, leading to downregulation of E2A/HEB target genes and lymphomagenesis in transgenic mice.","method":"Mammalian two-hybrid assay, luciferase reporter assay, RT-PCR, transgenic mouse model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2-3 — two-hybrid and reporter assay with in vivo transgenic phenotype, single lab","pmids":["17486074"],"is_preprint":false},{"year":2009,"finding":"Lyl1 and Scl show genetic redundancy for adult HSC survival; double conditional knockout mice show rapid loss of hematopoietic progenitors via apoptosis, while a single allele of Lyl1 (but not Scl) can rescue HSC function.","method":"Conditional double-knockout mouse model, bone marrow repopulation assays, flow cytometry, apoptosis assays","journal":"Cell stem cell","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with clean dose-dependent phenotype, replicated with multiple functional readouts","pmids":["19200805"],"is_preprint":false},{"year":2010,"finding":"LYL1 protein is degraded by the proteasome via a PEST sequence motif in its N-terminus; LYL1 is phosphorylated by MAPK at Ser36, but proteasomal degradation occurs in a phosphorylation-independent manner.","method":"Cell-based protein degradation assays, PEST motif mutagenesis, proteasome inhibitor treatment, site-directed mutagenesis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — mutagenesis with cell-based assays, single lab","pmids":["20844761"],"is_preprint":false},{"year":2010,"finding":"LYL1 is required for maturation of newly formed blood vessels in adult mice; Lyl1-deficient tumor vessels show enlarged lumens, reduced pericyte coverage, increased permeability, and upregulation of Tal-1/VE-Cadherin and Angiopoietin-2; LYL1 controls expression of molecules involved in vascular stabilization in endothelial cells.","method":"Lyl1 knockout mouse tumor implantation model, Matrigel assay, aortic explant assay, hematopoietic reconstitution, LYL1 knockdown in human endothelial cells","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple in vivo and in vitro models with defined vascular phenotypes","pmids":["20418284"],"is_preprint":false},{"year":2012,"finding":"TAL1, LYL1, and LMO2 directly bind an Ebox-GATA composite element in the ANGIOPOIETIN-2 (ANG-2) promoter in human endothelial cells; LMO2 assembles TAL1-E47, LYL1-LYL1 or LYL1-TAL1 dimers with GATA2 into complexes that activate endogenous ANG-2 expression.","method":"Chromatin immunoprecipitation (ChIP), knockdown experiments, transient transfection reporter assay, promoter mutagenesis","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1-2 — direct ChIP occupancy, promoter mutagenesis, and functional knockdown with multiple orthogonal methods","pmids":["22792348"],"is_preprint":false},{"year":2012,"finding":"Lyl1 is required for lymphoid specification and maintenance of early T lineage progenitors (ETPs); Lyl1 deficiency causes apoptosis and blocked differentiation in ETPs and DN2 thymocytes; Gfi1 was identified as a critical transcriptional target of Lyl1 in T-cell lymphopoiesis.","method":"Lyl1 knockout mouse, flow cytometry, apoptosis assays, gene expression profiling, ChIP","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined cellular phenotypes, target gene identification","pmids":["22404772"],"is_preprint":false},{"year":2012,"finding":"Lyl1 deficiency results in a stress erythropoiesis phenotype: partial differentiation arrest and enhanced apoptosis with decreased Bcl-xL in bone marrow, compensatory splenic erythropoiesis, and hypersensitivity to erythropoietin in erythroid progenitors.","method":"Knockout mouse model, progenitor assays, flow cytometry, competitive reconstitution assay, qRT-PCR","journal":"Experimental hematology","confidence":"High","confidence_rationale":"Tier 2 — multiple functional assays in KO model with mechanistic gene expression analysis","pmids":["21420467"],"is_preprint":false},{"year":2012,"finding":"LYL1 and CREB1 co-occupy the STMN1 (Op18/stathmin) promoter in vivo and together co-regulate STMN1 expression; NLI, LMO2, and GATA2 potentiate LYL1-mediated activation of STMN1 promoter, while TAL1 has no effect on this promoter.","method":"ChIP-chip, promoter reporter assay, site-directed mutagenesis, shRNA knockdown","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-chip with promoter mutagenesis and KD, single lab","pmids":["23000483"],"is_preprint":false},{"year":2013,"finding":"Lyl1 (but not Scl) is required for all oncogenic functions of Lmo2 in T-ALL, including upregulation of a stem cell-like gene signature, aberrant self-renewal of thymocytes, and leukemia generation; LMO2 must recruit LYL1 to DNA to mediate leukemic activity.","method":"Transgenic mouse model (Lmo2-Tg × Lyl1-KO or Scl-KO), serial transplantation, gene expression profiling","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in vivo with multiple functional readouts and human ETP-ALL validation","pmids":["23926305"],"is_preprint":false},{"year":2014,"finding":"LYL1 is required for endothelial barrier integrity in adult mouse lungs; LYL1 knockdown downregulates ARHGAP21 and ARHGAP24 (Rho GTPase-activating proteins), leading to increased RhoA activity and actin stress fiber formation; Lyl1-deficient mice show impaired VE-cadherin/p120-catenin recruitment to adherens junctions and increased lung vascular permeability; LYL1 acts upstream of VE-cadherin and the GTPases Rap1 and RhoA.","method":"LYL1 knockdown in human endothelial cells, Lyl1 knockout mouse, immunofluorescence, Evans blue permeability assay, RhoA activity assay","journal":"American journal of physiology. Lung cellular and molecular physiology","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function in vitro and in vivo with defined molecular pathway and multiple readouts","pmids":["24532287"],"is_preprint":false},{"year":2018,"finding":"Lyl1 can maintain primitive erythropoiesis in the absence of Scl; LYL1 exclusively binds a subset of SCL targets including GATA1 in erythroid cells, and double knockout of Scl and Lyl1 causes loss of Gata1 and SCL-GATA1 complex target genes, resulting in embryonic lethality from loss of erythropoiesis.","method":"Conditional double-knockout mouse, ChIP-seq (human erythroleukemia cell line), gene expression profiling","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with ChIP-seq and transcriptomics establishing binding site specificity","pmids":["30185409"],"is_preprint":false},{"year":2019,"finding":"Lyl1 is essential for expression of a stem cell-like gene expression program in thymocytes induced by NUP98-HOXD13 and required for thymocyte self-renewal; Lmo2-mediated thymocyte self-renewal also requires Lyl1.","method":"NHD13-transgenic × Lyl1-knockout mouse, serial transplantation, transcriptome analysis","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with functional self-renewal assay and transcriptome analysis","pmids":["30700838"],"is_preprint":false},{"year":2019,"finding":"Scl and Lyl1 share functional roles in platelet production by redundantly regulating expression of partner transcription factors Gata1, Fli1, Nfe2, and others via shared E-box binding sites enriched for Gata1, Ets, and Runx1 motifs in megakaryocytes.","method":"Conditional double-knockout mouse (Pf4-Cre), platelet aggregation assay, gene expression analysis, ChIP-seq E-box binding site analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — conditional DKO with multiple cellular and molecular phenotypes and genomic binding data","pmids":["31300405"],"is_preprint":false},{"year":2021,"finding":"Lyl-1 disruption in yolk sac macrophage progenitors (via disruption of its bHLH domain) leads to increased emergence but defective differentiation of primitive macrophage progenitors and reduced microglia production in the brain, with associated disruption of embryonic patterning and neurodevelopment gene sets.","method":"Lyl1 knockout mouse (bHLH domain disruption), transcriptomic analysis, flow cytometry, immunohistochemistry","journal":"Communications biology","confidence":"Medium","confidence_rationale":"Tier 2 — KO with defined cellular phenotype and transcriptomics, single lab","pmids":["34887504"],"is_preprint":false},{"year":2022,"finding":"LYL1 is required for assembly of the larger AETFC complex (containing AML1-ETO, CBFβ, HEB, E2A, LYL1, LMO2, LDB1) in t(8;21) AML; LYL1-containing AETFC preferentially binds active enhancers; LYL1 recruits coactivator CARM1 to chromatin to promote AE-dependent gene activation.","method":"Biochemical complex purification, co-immunoprecipitation, ChIP-seq, genomic binding analysis, functional gene expression assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — biochemical complex assembly with genomic binding and functional validation using multiple orthogonal approaches","pmids":["36215477"],"is_preprint":false},{"year":2024,"finding":"LYL1 expression is upregulated by BHLHE40 in response to supraphysiological androgen; LYL1 forms a complex with BHLHE40 and the androgen receptor (AR); LYL1 mediates SAL-induced cellular senescence partly through regulation of p27kip1; AR and BHLHE40 are recruited to the LYL1 gene locus.","method":"ChIP-seq, RNA-seq, co-immunoprecipitation, siRNA knockdown, rescue experiments, qRT-PCR","journal":"Cell communication and signaling","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-seq, Co-IP, and rescue experiments, single lab in a non-canonical cell type","pmids":["39668349"],"is_preprint":false},{"year":2024,"finding":"SPI1 (PU.1) regulates LYL1 as a downstream transcriptional target during endothelial-to-hematopoietic transition; LYL1 overexpression rescues the lymphoid lineage potential lost upon SPI1 knockdown.","method":"SPI1 knockdown, LYL1 overexpression rescue, multi-omic analysis of human pluripotent stem cell-derived EHT","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 — genetic rescue with multi-omic analysis, single lab","pmids":["39108738"],"is_preprint":false}],"current_model":"LYL1 is a basic helix-loop-helix (bHLH) transcription factor that heterodimerizes with E2a proteins (E12/E47) via its HLH motif to bind a specific DNA consensus sequence, interacts with NF-κB1 p105 (via bHLH-ankyrin interaction), CREB1 (via its N-terminal domain), and assembles into multiprotein complexes including the AETFC complex (with AML1-ETO, LMO2, LDB1) by recruiting the coactivator CARM1; it is subject to proteasomal degradation directed by an N-terminal PEST sequence independent of MAPK phosphorylation at Ser36; and it functions redundantly with SCL/TAL1 in adult HSC maintenance, primitive erythropoiesis, megakaryopoiesis, and thymocyte self-renewal, while playing non-redundant roles in B-cell development, endothelial barrier maturation (upstream of Rap1/RhoA and VE-cadherin), and ETP-ALL driven by LMO2."},"narrative":{"teleology":[{"year":1989,"claim":"Identification of LYL1 at a T-ALL translocation breakpoint established it as a new bHLH transcription factor family member, raising the question of its DNA-binding specificity and normal cellular function.","evidence":"Molecular cloning and sequence analysis from t(7;19) T-ALL","pmids":["2752424"],"confidence":"High","gaps":["No binding partners or DNA target specificity determined","Normal tissue expression pattern not fully characterized"]},{"year":1996,"claim":"Demonstrating that LYL1 heterodimerizes with E2A proteins and binds a distinct DNA consensus sequence resolved how LYL1 achieves target gene specificity distinct from E2A homodimers.","evidence":"Yeast two-hybrid, Co-IP, PCR-assisted binding site selection","pmids":["8628307"],"confidence":"High","gaps":["Endogenous genomic targets not identified","Functional consequence of DNA binding on gene expression unknown"]},{"year":1999,"claim":"Discovery that LYL1 physically interacts with NF-κB1 p105 and represses NF-κB-dependent transcription revealed a novel bHLH-ankyrin interaction mechanism and a potential link between LYL1 dysregulation and inflammatory/immune signaling.","evidence":"Yeast two-hybrid, in vitro binding, Co-IP, NF-κB reporter assays in T cells","pmids":["10023675"],"confidence":"High","gaps":["Physiological relevance of LYL1-NF-κB interaction in hematopoiesis not tested in vivo","Whether this interaction occurs at endogenous protein levels unclear"]},{"year":2006,"claim":"Lyl1 knockout mice established that LYL1 is required for HSC self-renewal and B-cell differentiation in vivo, moving it from an oncogene candidate to a physiological regulator of hematopoiesis; parallel promoter analysis revealed GATA-2 and Ets factor regulation of Lyl1 expression, while demonstrating that Lyl1 cannot substitute for Scl in early hematopoietic specification.","evidence":"Lyl1-KO mice with competitive repopulation, transgenic promoter analysis, ChIP, ES cell rescue","pmids":["16514064","17053063"],"confidence":"High","gaps":["Specific transcriptional targets of LYL1 in HSCs not identified","Degree of redundancy with SCL not genetically tested"]},{"year":2007,"claim":"Identification of LYL1-CREB1 interaction and p300/CBP coactivator recruitment defined a phosphorylation-independent transcriptional activation mechanism, while overexpression studies showed LYL1 can sequester E2A and promote lymphomagenesis.","evidence":"Co-IP with domain mapping, ChIP-chip, reporter assays; mammalian two-hybrid and transgenic mouse lymphoma model","pmids":["18160048","17486074"],"confidence":"High","gaps":["Whether LYL1-CREB1 complexes operate in normal hematopoiesis vs. leukemia not distinguished","Genome-wide target overlap between LYL1-E2A and LYL1-CREB1 complexes unknown"]},{"year":2009,"claim":"Conditional double-knockout of Lyl1 and Scl proved genetic redundancy for adult HSC survival, with a single Lyl1 allele sufficient for rescue, establishing LYL1 as the more potent factor in adult HSC maintenance.","evidence":"Conditional DKO mice, bone marrow repopulation, apoptosis assays","pmids":["19200805"],"confidence":"High","gaps":["Molecular basis for why one Lyl1 allele suffices but one Scl allele does not was not resolved","Shared vs. unique chromatin targets not mapped"]},{"year":2010,"claim":"Characterization of LYL1 protein turnover revealed PEST-dependent proteasomal degradation independent of MAPK-mediated Ser36 phosphorylation, while in vivo vascular studies established LYL1 as a regulator of blood vessel maturation controlling VE-cadherin, pericyte coverage, and angiopoietin-2.","evidence":"PEST mutagenesis with proteasome inhibitors; Lyl1-KO tumor implantation, Matrigel assay, LYL1 knockdown in endothelial cells","pmids":["20844761","20418284"],"confidence":"High","gaps":["E3 ubiquitin ligase targeting LYL1 not identified","Transcriptional vs. post-transcriptional regulation of vascular targets not fully separated"]},{"year":2012,"claim":"A series of studies defined LYL1's multilineage functions: LYL1 occupies the ANG-2 promoter with LMO2/GATA2 in endothelial cells, maintains early T-cell progenitors via Gfi1 activation, supports erythropoiesis by regulating Bcl-xL, and co-regulates STMN1 with CREB1, collectively establishing LYL1 as a versatile bHLH factor with context-dependent target gene programs.","evidence":"ChIP, knockdown, reporter assays in endothelial cells; Lyl1-KO mouse ETP/erythroid phenotyping; ChIP-chip for STMN1 promoter","pmids":["22792348","22404772","21420467","23000483"],"confidence":"High","gaps":["Whether LYL1 activates different gene programs through different partner complexes (E2A vs. CREB1 vs. LMO2) in the same cell type not resolved","Full genome-wide target repertoire in primary cells not mapped at this point"]},{"year":2013,"claim":"Genetic epistasis demonstrated that LYL1, but not SCL, is essential for LMO2-driven thymocyte self-renewal and T-ALL, establishing a non-redundant oncogenic requirement and explaining why LYL1 is specifically co-expressed with LMO2 in ETP-ALL.","evidence":"Lmo2-Tg × Lyl1-KO vs. Scl-KO mice, serial transplantation, gene expression profiling","pmids":["23926305"],"confidence":"High","gaps":["Direct LYL1-LMO2 binding sites in leukemic thymocytes not mapped by ChIP-seq","Whether LYL1 is sufficient or merely required for LMO2 oncogenic activity unknown"]},{"year":2014,"claim":"Mechanistic dissection of the vascular barrier phenotype showed LYL1 acts upstream of VE-cadherin and Rap1/RhoA by transcriptionally controlling ARHGAP21 and ARHGAP24, providing a molecular pathway for LYL1's endothelial function.","evidence":"LYL1 knockdown in HUVECs, Lyl1-KO mouse lung permeability (Evans blue), RhoA activity assay, immunofluorescence","pmids":["24532287"],"confidence":"High","gaps":["Whether LYL1 directly binds ARHGAP21/24 promoters not shown by ChIP","Contribution of other LYL1 vascular targets to barrier function not assessed"]},{"year":2018,"claim":"ChIP-seq in erythroid cells revealed that LYL1 exclusively occupies a subset of SCL targets including the GATA1 locus, and double knockout confirmed that LYL1 maintains primitive erythropoiesis by sustaining GATA1 expression when SCL is absent.","evidence":"Conditional Scl/Lyl1 DKO, ChIP-seq in human erythroleukemia cells, transcriptomics","pmids":["30185409"],"confidence":"High","gaps":["Whether LYL1 binds the same sites in primary erythroid progenitors vs. cell lines not confirmed","Structural basis for LYL1 vs. SCL binding site preference unknown"]},{"year":2019,"claim":"Studies extended LYL1's non-redundant oncogenic role to NUP98-HOXD13-driven leukemia and confirmed redundancy with SCL in megakaryopoiesis, where both factors regulate Gata1, Fli1, and Nfe2 through shared E-box sites.","evidence":"NHD13-Tg × Lyl1-KO, serial transplantation; Pf4-Cre conditional DKO, platelet assays, ChIP-seq","pmids":["30700838","31300405"],"confidence":"High","gaps":["Whether LYL1-dependent self-renewal programs are identical across different oncogene contexts not compared","Megakaryocyte-specific LYL1 ChIP-seq not performed"]},{"year":2021,"claim":"Disruption of LYL1's bHLH domain in yolk sac macrophage progenitors revealed a role in primitive macrophage differentiation and microglia production, expanding LYL1 function beyond definitive hematopoiesis to embryonic tissue-resident immune cell development.","evidence":"Lyl1-KO (bHLH disruption), flow cytometry, transcriptomics, immunohistochemistry in embryonic brain","pmids":["34887504"],"confidence":"Medium","gaps":["Whether residual truncated LYL1 protein retains partial activity not excluded","Direct transcriptional targets in macrophage progenitors not identified"]},{"year":2022,"claim":"Biochemical purification of the AETFC complex in t(8;21) AML demonstrated that LYL1 is a core subunit required for complex assembly at active enhancers and recruits the coactivator CARM1 to promote AML1-ETO-dependent gene activation, providing a mechanistic basis for LYL1's role in leukemia maintenance.","evidence":"Complex purification, Co-IP, ChIP-seq, gene expression assays in Kasumi-1 cells","pmids":["36215477"],"confidence":"High","gaps":["Whether CARM1 recruitment is specific to AETFC or shared with other LYL1 complexes unknown","Therapeutic vulnerability of LYL1 within AETFC not tested"]},{"year":2024,"claim":"New contexts for LYL1 function emerged: BHLHE40/AR-mediated upregulation of LYL1 in androgen-induced senescence and SPI1/PU.1-dependent regulation of LYL1 during endothelial-to-hematopoietic transition broadened the regulatory network governing and governed by LYL1.","evidence":"ChIP-seq, RNA-seq, Co-IP, siRNA rescue in prostate cancer cells; SPI1-KD/LYL1 rescue in human PSC-derived EHT","pmids":["39668349","39108738"],"confidence":"Medium","gaps":["LYL1-BHLHE40-AR complex stoichiometry and genomic targets not fully defined","Whether SPI1-LYL1 axis operates in vivo during EHT not confirmed"]},{"year":null,"claim":"Key unresolved questions include the structural basis for LYL1 vs. SCL target selectivity, the identity of the E3 ligase mediating LYL1 proteasomal turnover, genome-wide comparison of LYL1 complex composition across cell types, and whether LYL1 can be therapeutically targeted in LMO2-driven T-ALL or AML1-ETO AML.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model of LYL1 or LYL1-containing complexes exists","E3 ubiquitin ligase for LYL1 degradation not identified","No pharmacological strategy to target LYL1 in leukemia has been tested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,1,16]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,5,6,10,11,13,20]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,5,10,20]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[5,10,11,13,16,20]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[3,7,16,19]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[14,17,20]}],"complexes":["AETFC (AML1-ETO/LYL1/LMO2/LDB1/HEB/E2A/CBFβ)","LYL1-E2A heterodimer","LMO2/GATA2/LYL1/TAL1 enhancer complex"],"partners":["TCF3","LMO2","LDB1","GATA2","CREB1","NFKB1","CARM1","BHLHE40"],"other_free_text":[]},"mechanistic_narrative":"LYL1 is a basic helix-loop-helix (bHLH) transcription factor that functions as a critical regulator of hematopoietic stem cell maintenance, multilineage blood cell differentiation, and vascular maturation. LYL1 heterodimerizes with E2A proteins (E12/E47) via its HLH domain to bind a preferred DNA consensus sequence (5'-AACAGATG(T/g)T-3'), and acts redundantly with SCL/TAL1 in adult HSC survival, primitive erythropoiesis, and megakaryopoiesis, while playing non-redundant roles in B-cell development, early T-cell progenitor maintenance (where it activates Gfi1), and endothelial barrier integrity through regulation of Rho GTPase-activating proteins (ARHGAP21/24), VE-cadherin junctional recruitment, and Rap1/RhoA signaling [PMID:8628307, PMID:19200805, PMID:30185409, PMID:31300405, PMID:22404772, PMID:24532287]. LYL1 assembles into multiprotein transcriptional complexes with LMO2, GATA2, and LDB1 at E-box/GATA composite elements on target promoters, interacts with CREB1 to recruit p300/CBP coactivators, and is a required component of the AETFC complex in t(8;21) AML where it recruits CARM1 to activate enhancer-driven gene expression [PMID:22792348, PMID:18160048, PMID:36215477]. LYL1 is essential for LMO2-driven thymocyte self-renewal and T-ALL initiation, establishing it as a non-redundant mediator of leukemogenic transcriptional programs [PMID:23926305, PMID:30700838]."},"prefetch_data":{"uniprot":{"accession":"P12980","full_name":"Protein lyl-1","aliases":["Class A basic helix-loop-helix protein 18","bHLHa18","Lymphoblastic leukemia-derived sequence 1"],"length_aa":280,"mass_kda":29.9,"function":"","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P12980/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LYL1","classification":"Not Classified","n_dependent_lines":12,"n_total_lines":1208,"dependency_fraction":0.009933774834437087},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/LYL1","total_profiled":1310},"omim":[{"mim_id":"604640","title":"T-CELL LEUKEMIA HOMEOBOX 3; TLX3","url":"https://www.omim.org/entry/604640"},{"mim_id":"600006","title":"REGULATORY FACTOR X, 1; RFX1","url":"https://www.omim.org/entry/600006"},{"mim_id":"300248","title":"INHIBITOR OF NUCLEAR FACTOR KAPPA-B KINASE, REGULATORY SUBUNIT GAMMA; IKBKG","url":"https://www.omim.org/entry/300248"},{"mim_id":"187040","title":"T-CELL ACUTE LYMPHOCYTIC LEUKEMIA 1; TAL1","url":"https://www.omim.org/entry/187040"},{"mim_id":"186855","title":"T-CELL ACUTE LYMPHOCYTIC LEUKEMIA 2; TAL2","url":"https://www.omim.org/entry/186855"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":33.8},{"tissue":"lymphoid tissue","ntpm":35.3}],"url":"https://www.proteinatlas.org/search/LYL1"},"hgnc":{"alias_symbol":["bHLHa18"],"prev_symbol":[]},"alphafold":{"accession":"P12980","domains":[{"cath_id":"4.10.280.10","chopping":"145-215","consensus_level":"medium","plddt":96.1935,"start":145,"end":215}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P12980","model_url":"https://alphafold.ebi.ac.uk/files/AF-P12980-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P12980-F1-predicted_aligned_error_v6.png","plddt_mean":65.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LYL1","jax_strain_url":"https://www.jax.org/strain/search?query=LYL1"},"sequence":{"accession":"P12980","fasta_url":"https://rest.uniprot.org/uniprotkb/P12980.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P12980/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P12980"}},"corpus_meta":[{"pmid":"2752424","id":"PMC_2752424","title":"lyl-1, a novel gene altered by chromosomal translocation in T cell leukemia, codes for a protein with a helix-loop-helix DNA binding motif.","date":"1989","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/2752424","citation_count":342,"is_preprint":false},{"pmid":"8142619","id":"PMC_8142619","title":"TAL1, TAL2 and LYL1: a family of basic helix-loop-helix proteins implicated in T cell acute leukaemia.","date":"1993","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/8142619","citation_count":117,"is_preprint":false},{"pmid":"19200805","id":"PMC_19200805","title":"Adult hematopoietic stem and progenitor cells require either Lyl1 or Scl for survival.","date":"2009","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/19200805","citation_count":111,"is_preprint":false},{"pmid":"16514064","id":"PMC_16514064","title":"The SCL relative LYL-1 is required for fetal and adult hematopoietic stem cell function and B-cell differentiation.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16514064","citation_count":70,"is_preprint":false},{"pmid":"17053063","id":"PMC_17053063","title":"The paralogous hematopoietic regulators Lyl1 and Scl are coregulated by Ets and GATA factors, but Lyl1 cannot rescue the early Scl-/- phenotype.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17053063","citation_count":67,"is_preprint":false},{"pmid":"23926305","id":"PMC_23926305","title":"Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23926305","citation_count":58,"is_preprint":false},{"pmid":"8628307","id":"PMC_8628307","title":"Helix-loop-helix proteins LYL1 and E2a form heterodimeric complexes with distinctive DNA-binding properties in hematolymphoid cells.","date":"1996","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8628307","citation_count":50,"is_preprint":false},{"pmid":"22772404","id":"PMC_22772404","title":"The transcription factor Lyl-1 regulates lymphoid specification and the maintenance of early T lineage progenitors.","date":"2012","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22772404","citation_count":49,"is_preprint":false},{"pmid":"2067848","id":"PMC_2067848","title":"Structure, chromosome mapping, and expression of the mouse Lyl-1 gene.","date":"1991","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/2067848","citation_count":48,"is_preprint":false},{"pmid":"17486074","id":"PMC_17486074","title":"Overexpression of a transcription factor LYL1 induces T- and B-cell lymphoma in mice.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17486074","citation_count":37,"is_preprint":false},{"pmid":"10023675","id":"PMC_10023675","title":"Physical interaction of the bHLH LYL1 protein and NF-kappaB1 p105.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10023675","citation_count":33,"is_preprint":false},{"pmid":"12659809","id":"PMC_12659809","title":"Comparative and functional analyses of LYL1 loci establish marsupial sequences as a model for phylogenetic footprinting.","date":"2003","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/12659809","citation_count":31,"is_preprint":false},{"pmid":"16094422","id":"PMC_16094422","title":"Oncogenic potential of the transcription factor LYL1 in acute myeloblastic leukemia.","date":"2005","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/16094422","citation_count":30,"is_preprint":false},{"pmid":"22058201","id":"PMC_22058201","title":"Characterization of a pediatric T-cell acute lymphoblastic leukemia patient with simultaneous LYL1 and LMO2 rearrangements.","date":"2011","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/22058201","citation_count":29,"is_preprint":false},{"pmid":"19608273","id":"PMC_19608273","title":"Multiple mechanisms induce ectopic expression of LYL1 in subsets of T-ALL cell lines.","date":"2009","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/19608273","citation_count":25,"is_preprint":false},{"pmid":"17112790","id":"PMC_17112790","title":"lyl-1 and tal-1/scl, two genes encoding closely related bHLH transcription factors, display highly overlapping expression patterns during cardiovascular and hematopoietic ontogeny.","date":"2006","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/17112790","citation_count":25,"is_preprint":false},{"pmid":"18160048","id":"PMC_18160048","title":"Lyl1 interacts with CREB1 and alters expression of CREB1 target genes.","date":"2007","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/18160048","citation_count":23,"is_preprint":false},{"pmid":"22792348","id":"PMC_22792348","title":"Angiopoietin-2 is a direct transcriptional target of TAL1, LYL1 and LMO2 in endothelial cells.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22792348","citation_count":22,"is_preprint":false},{"pmid":"35842703","id":"PMC_35842703","title":"Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia.","date":"2022","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/35842703","citation_count":21,"is_preprint":false},{"pmid":"35958877","id":"PMC_35958877","title":"BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia.","date":"2022","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/35958877","citation_count":16,"is_preprint":false},{"pmid":"20418284","id":"PMC_20418284","title":"LYL1 activity is required for the maturation of newly formed blood vessels in adulthood.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20418284","citation_count":15,"is_preprint":false},{"pmid":"21420467","id":"PMC_21420467","title":"LYL-1 deficiency induces a stress erythropoiesis.","date":"2011","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/21420467","citation_count":15,"is_preprint":false},{"pmid":"24532287","id":"PMC_24532287","title":"Lung endothelial barrier disruption in Lyl1-deficient mice.","date":"2014","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24532287","citation_count":14,"is_preprint":false},{"pmid":"31300405","id":"PMC_31300405","title":"Shared roles for Scl and Lyl1 in murine platelet production and function.","date":"2019","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/31300405","citation_count":12,"is_preprint":false},{"pmid":"30700838","id":"PMC_30700838","title":"The NUP98-HOXD13 fusion oncogene induces thymocyte self-renewal via Lmo2/Lyl1.","date":"2019","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/30700838","citation_count":12,"is_preprint":false},{"pmid":"36215477","id":"PMC_36215477","title":"LYL1 facilitates AETFC assembly and gene activation by recruiting CARM1 in t(8;21) AML.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/36215477","citation_count":11,"is_preprint":false},{"pmid":"30185409","id":"PMC_30185409","title":"A novel role for Lyl1 in primitive erythropoiesis.","date":"2018","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/30185409","citation_count":10,"is_preprint":false},{"pmid":"34887504","id":"PMC_34887504","title":"Lyl-1 regulates primitive macrophages and microglia development.","date":"2021","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/34887504","citation_count":10,"is_preprint":false},{"pmid":"21387538","id":"PMC_21387538","title":"A new allele of Lyl1 confirms its important role in hematopoietic stem cell function.","date":"2011","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/21387538","citation_count":7,"is_preprint":false},{"pmid":"20844761","id":"PMC_20844761","title":"LYL1 degradation by the proteasome is directed by a N-terminal PEST rich site in a phosphorylation-independent manner.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20844761","citation_count":7,"is_preprint":false},{"pmid":"23000483","id":"PMC_23000483","title":"Suspected leukemia oncoproteins CREB1 and LYL1 regulate Op18/STMN1 expression.","date":"2012","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23000483","citation_count":6,"is_preprint":false},{"pmid":"39108738","id":"PMC_39108738","title":"SPI1-KLF1/LYL1 axis regulates lineage commitment during endothelial-to-hematopoietic transition from human pluripotent stem cells.","date":"2024","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/39108738","citation_count":6,"is_preprint":false},{"pmid":"20705338","id":"PMC_20705338","title":"The expansion of T-cells and hematopoietic progenitors as a result of overexpression of the lymphoblastic leukemia gene, Lyl1 can support leukemia formation.","date":"2010","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/20705338","citation_count":6,"is_preprint":false},{"pmid":"39668349","id":"PMC_39668349","title":"Functional circuits of LYL1 controlled by supraphysiological androgen in prostate cancer cells to regulate cell senescence.","date":"2024","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/39668349","citation_count":4,"is_preprint":false},{"pmid":"33022858","id":"PMC_33022858","title":"In Lyl1-/- mice, adipose stem cell vascular niche impairment leads to premature development of fat tissues.","date":"2020","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/33022858","citation_count":3,"is_preprint":false},{"pmid":"36119114","id":"PMC_36119114","title":"Lyl1-deficiency promotes inflammatory responses and increases mycobacterial burden in response to Mycobacterium tuberculosis infection in mice.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36119114","citation_count":1,"is_preprint":false},{"pmid":"19176012","id":"PMC_19176012","title":"[Expression of transcription factor LYL1 in leukemia and its possible role in leukemogenesis].","date":"2008","source":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","url":"https://pubmed.ncbi.nlm.nih.gov/19176012","citation_count":1,"is_preprint":false},{"pmid":"19671288","id":"PMC_19671288","title":"[Abnormal expression of transcription factors LYL1 and LMO2 and interaction between them in myeloid leukemia].","date":"2009","source":"Zhonghua yi xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/19671288","citation_count":1,"is_preprint":false},{"pmid":"40287790","id":"PMC_40287790","title":"Role of different Lyl1 transcripts in zebrafish primitive hematopoiesis.","date":"2025","source":"Yi chuan = Hereditas","url":"https://pubmed.ncbi.nlm.nih.gov/40287790","citation_count":0,"is_preprint":false},{"pmid":"39611066","id":"PMC_39611066","title":"Multiple primary tumors in a patient with non‑small‑cell lung cancer harboring mutations in ERCC6 and LYL1: A case report.","date":"2024","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/39611066","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":21228,"output_tokens":5285,"usd":0.07148},"stage2":{"model":"claude-opus-4-6","input_tokens":8848,"output_tokens":4188,"usd":0.22341},"total_usd":0.29489,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1989,\n      \"finding\": \"LYL1 encodes a protein containing a helix-loop-helix (HLH) DNA-binding motif, structurally related to Myc, MyoD, and immunoglobulin enhancer-binding proteins, first identified at a chromosomal translocation breakpoint (t(7;19)) in T-ALL.\",\n      \"method\": \"Molecular cloning, sequence analysis, structural prediction\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning with structural characterization, foundational paper, 342 citations\",\n      \"pmids\": [\"2752424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"LYL1 forms heterodimeric complexes with E2a proteins (E12 and E47) via their HLH motifs, and these endogenous LYL1-E2a complexes bind a preferred DNA sequence (5'-AACAGATG(T/g)T-3') distinct from the muE2 site recognized by E2a homodimers.\",\n      \"method\": \"Yeast two-hybrid screen, in vitro binding assay, co-immunoprecipitation, PCR-assisted site selection\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including in vitro reconstitution, Co-IP, and DNA-binding site selection\",\n      \"pmids\": [\"8628307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"LYL1 physically interacts with NF-κB1 p105 (the precursor of p50) via the bHLH motif of LYL1 and the ankyrin-like motifs of p105; ectopic LYL1 expression in T cells significantly reduces NF-κB-dependent transcription.\",\n      \"method\": \"Yeast two-hybrid screen, in vitro binding assay, co-immunoprecipitation in mammalian cells, transcription reporter assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — interaction confirmed in vitro and in vivo with functional transcriptional readout\",\n      \"pmids\": [\"10023675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Lyl1 is required for normal hematopoietic stem cell (HSC) function and B-cell differentiation in vivo; Lyl1-null mice show reduced HSC frequency (LSK, LSK-SP) and severely impaired competitive reconstitution, particularly of B and T lineages.\",\n      \"method\": \"Knockout mouse model, competitive bone marrow reconstitution assay, flow cytometry, colony-forming assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with multiple defined cellular phenotypes and functional reconstitution assays\",\n      \"pmids\": [\"16514064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Lyl1 promoter activity in hematopoietic progenitor and endothelial cells is driven by conserved binding sites occupied in vivo by GATA-2 and Ets factors (Fli1, Elf1, Erg, PU.1); despite co-regulation with Scl by the same factors, Lyl1 cannot rescue hematopoietic differentiation in Scl-/- ES cells.\",\n      \"method\": \"Transgenic mouse promoter assay, chromatin immunoprecipitation (ChIP), ES cell differentiation rescue assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vivo ChIP, transgenic promoter analysis, and functional rescue experiments\",\n      \"pmids\": [\"17053063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"LYL1 interacts with CREB1 via the N-terminal domain of LYL1 and the Q2/KID domains of CREB1; these complexes recruit p300/CBP (histone acetyltransferases) independently of CREB1 Ser133 phosphorylation and activate CREB1 target gene promoters including Id1, Id3, cyclin D3, Brca1, Btg2, and Egr1.\",\n      \"method\": \"Co-immunoprecipitation, luciferase reporter assay, ChIP-chip, domain-mapping mutagenesis\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP with domain mapping, ChIP-chip genome-wide, and functional reporter assays\",\n      \"pmids\": [\"18160048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Excess LYL1 blocks E2A dimerization and inhibits E2A regulatory activity on the CD4 promoter, leading to downregulation of E2A/HEB target genes and lymphomagenesis in transgenic mice.\",\n      \"method\": \"Mammalian two-hybrid assay, luciferase reporter assay, RT-PCR, transgenic mouse model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — two-hybrid and reporter assay with in vivo transgenic phenotype, single lab\",\n      \"pmids\": [\"17486074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Lyl1 and Scl show genetic redundancy for adult HSC survival; double conditional knockout mice show rapid loss of hematopoietic progenitors via apoptosis, while a single allele of Lyl1 (but not Scl) can rescue HSC function.\",\n      \"method\": \"Conditional double-knockout mouse model, bone marrow repopulation assays, flow cytometry, apoptosis assays\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with clean dose-dependent phenotype, replicated with multiple functional readouts\",\n      \"pmids\": [\"19200805\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"LYL1 protein is degraded by the proteasome via a PEST sequence motif in its N-terminus; LYL1 is phosphorylated by MAPK at Ser36, but proteasomal degradation occurs in a phosphorylation-independent manner.\",\n      \"method\": \"Cell-based protein degradation assays, PEST motif mutagenesis, proteasome inhibitor treatment, site-directed mutagenesis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis with cell-based assays, single lab\",\n      \"pmids\": [\"20844761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"LYL1 is required for maturation of newly formed blood vessels in adult mice; Lyl1-deficient tumor vessels show enlarged lumens, reduced pericyte coverage, increased permeability, and upregulation of Tal-1/VE-Cadherin and Angiopoietin-2; LYL1 controls expression of molecules involved in vascular stabilization in endothelial cells.\",\n      \"method\": \"Lyl1 knockout mouse tumor implantation model, Matrigel assay, aortic explant assay, hematopoietic reconstitution, LYL1 knockdown in human endothelial cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple in vivo and in vitro models with defined vascular phenotypes\",\n      \"pmids\": [\"20418284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TAL1, LYL1, and LMO2 directly bind an Ebox-GATA composite element in the ANGIOPOIETIN-2 (ANG-2) promoter in human endothelial cells; LMO2 assembles TAL1-E47, LYL1-LYL1 or LYL1-TAL1 dimers with GATA2 into complexes that activate endogenous ANG-2 expression.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), knockdown experiments, transient transfection reporter assay, promoter mutagenesis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct ChIP occupancy, promoter mutagenesis, and functional knockdown with multiple orthogonal methods\",\n      \"pmids\": [\"22792348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Lyl1 is required for lymphoid specification and maintenance of early T lineage progenitors (ETPs); Lyl1 deficiency causes apoptosis and blocked differentiation in ETPs and DN2 thymocytes; Gfi1 was identified as a critical transcriptional target of Lyl1 in T-cell lymphopoiesis.\",\n      \"method\": \"Lyl1 knockout mouse, flow cytometry, apoptosis assays, gene expression profiling, ChIP\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular phenotypes, target gene identification\",\n      \"pmids\": [\"22404772\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Lyl1 deficiency results in a stress erythropoiesis phenotype: partial differentiation arrest and enhanced apoptosis with decreased Bcl-xL in bone marrow, compensatory splenic erythropoiesis, and hypersensitivity to erythropoietin in erythroid progenitors.\",\n      \"method\": \"Knockout mouse model, progenitor assays, flow cytometry, competitive reconstitution assay, qRT-PCR\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays in KO model with mechanistic gene expression analysis\",\n      \"pmids\": [\"21420467\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"LYL1 and CREB1 co-occupy the STMN1 (Op18/stathmin) promoter in vivo and together co-regulate STMN1 expression; NLI, LMO2, and GATA2 potentiate LYL1-mediated activation of STMN1 promoter, while TAL1 has no effect on this promoter.\",\n      \"method\": \"ChIP-chip, promoter reporter assay, site-directed mutagenesis, shRNA knockdown\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-chip with promoter mutagenesis and KD, single lab\",\n      \"pmids\": [\"23000483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Lyl1 (but not Scl) is required for all oncogenic functions of Lmo2 in T-ALL, including upregulation of a stem cell-like gene signature, aberrant self-renewal of thymocytes, and leukemia generation; LMO2 must recruit LYL1 to DNA to mediate leukemic activity.\",\n      \"method\": \"Transgenic mouse model (Lmo2-Tg × Lyl1-KO or Scl-KO), serial transplantation, gene expression profiling\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo with multiple functional readouts and human ETP-ALL validation\",\n      \"pmids\": [\"23926305\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LYL1 is required for endothelial barrier integrity in adult mouse lungs; LYL1 knockdown downregulates ARHGAP21 and ARHGAP24 (Rho GTPase-activating proteins), leading to increased RhoA activity and actin stress fiber formation; Lyl1-deficient mice show impaired VE-cadherin/p120-catenin recruitment to adherens junctions and increased lung vascular permeability; LYL1 acts upstream of VE-cadherin and the GTPases Rap1 and RhoA.\",\n      \"method\": \"LYL1 knockdown in human endothelial cells, Lyl1 knockout mouse, immunofluorescence, Evans blue permeability assay, RhoA activity assay\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function in vitro and in vivo with defined molecular pathway and multiple readouts\",\n      \"pmids\": [\"24532287\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Lyl1 can maintain primitive erythropoiesis in the absence of Scl; LYL1 exclusively binds a subset of SCL targets including GATA1 in erythroid cells, and double knockout of Scl and Lyl1 causes loss of Gata1 and SCL-GATA1 complex target genes, resulting in embryonic lethality from loss of erythropoiesis.\",\n      \"method\": \"Conditional double-knockout mouse, ChIP-seq (human erythroleukemia cell line), gene expression profiling\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with ChIP-seq and transcriptomics establishing binding site specificity\",\n      \"pmids\": [\"30185409\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Lyl1 is essential for expression of a stem cell-like gene expression program in thymocytes induced by NUP98-HOXD13 and required for thymocyte self-renewal; Lmo2-mediated thymocyte self-renewal also requires Lyl1.\",\n      \"method\": \"NHD13-transgenic × Lyl1-knockout mouse, serial transplantation, transcriptome analysis\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with functional self-renewal assay and transcriptome analysis\",\n      \"pmids\": [\"30700838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Scl and Lyl1 share functional roles in platelet production by redundantly regulating expression of partner transcription factors Gata1, Fli1, Nfe2, and others via shared E-box binding sites enriched for Gata1, Ets, and Runx1 motifs in megakaryocytes.\",\n      \"method\": \"Conditional double-knockout mouse (Pf4-Cre), platelet aggregation assay, gene expression analysis, ChIP-seq E-box binding site analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional DKO with multiple cellular and molecular phenotypes and genomic binding data\",\n      \"pmids\": [\"31300405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Lyl-1 disruption in yolk sac macrophage progenitors (via disruption of its bHLH domain) leads to increased emergence but defective differentiation of primitive macrophage progenitors and reduced microglia production in the brain, with associated disruption of embryonic patterning and neurodevelopment gene sets.\",\n      \"method\": \"Lyl1 knockout mouse (bHLH domain disruption), transcriptomic analysis, flow cytometry, immunohistochemistry\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO with defined cellular phenotype and transcriptomics, single lab\",\n      \"pmids\": [\"34887504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LYL1 is required for assembly of the larger AETFC complex (containing AML1-ETO, CBFβ, HEB, E2A, LYL1, LMO2, LDB1) in t(8;21) AML; LYL1-containing AETFC preferentially binds active enhancers; LYL1 recruits coactivator CARM1 to chromatin to promote AE-dependent gene activation.\",\n      \"method\": \"Biochemical complex purification, co-immunoprecipitation, ChIP-seq, genomic binding analysis, functional gene expression assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical complex assembly with genomic binding and functional validation using multiple orthogonal approaches\",\n      \"pmids\": [\"36215477\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LYL1 expression is upregulated by BHLHE40 in response to supraphysiological androgen; LYL1 forms a complex with BHLHE40 and the androgen receptor (AR); LYL1 mediates SAL-induced cellular senescence partly through regulation of p27kip1; AR and BHLHE40 are recruited to the LYL1 gene locus.\",\n      \"method\": \"ChIP-seq, RNA-seq, co-immunoprecipitation, siRNA knockdown, rescue experiments, qRT-PCR\",\n      \"journal\": \"Cell communication and signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq, Co-IP, and rescue experiments, single lab in a non-canonical cell type\",\n      \"pmids\": [\"39668349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SPI1 (PU.1) regulates LYL1 as a downstream transcriptional target during endothelial-to-hematopoietic transition; LYL1 overexpression rescues the lymphoid lineage potential lost upon SPI1 knockdown.\",\n      \"method\": \"SPI1 knockdown, LYL1 overexpression rescue, multi-omic analysis of human pluripotent stem cell-derived EHT\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic rescue with multi-omic analysis, single lab\",\n      \"pmids\": [\"39108738\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LYL1 is a basic helix-loop-helix (bHLH) transcription factor that heterodimerizes with E2a proteins (E12/E47) via its HLH motif to bind a specific DNA consensus sequence, interacts with NF-κB1 p105 (via bHLH-ankyrin interaction), CREB1 (via its N-terminal domain), and assembles into multiprotein complexes including the AETFC complex (with AML1-ETO, LMO2, LDB1) by recruiting the coactivator CARM1; it is subject to proteasomal degradation directed by an N-terminal PEST sequence independent of MAPK phosphorylation at Ser36; and it functions redundantly with SCL/TAL1 in adult HSC maintenance, primitive erythropoiesis, megakaryopoiesis, and thymocyte self-renewal, while playing non-redundant roles in B-cell development, endothelial barrier maturation (upstream of Rap1/RhoA and VE-cadherin), and ETP-ALL driven by LMO2.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"LYL1 is a basic helix-loop-helix (bHLH) transcription factor that functions as a critical regulator of hematopoietic stem cell maintenance, multilineage blood cell differentiation, and vascular maturation. LYL1 heterodimerizes with E2A proteins (E12/E47) via its HLH domain to bind a preferred DNA consensus sequence (5'-AACAGATG(T/g)T-3'), and acts redundantly with SCL/TAL1 in adult HSC survival, primitive erythropoiesis, and megakaryopoiesis, while playing non-redundant roles in B-cell development, early T-cell progenitor maintenance (where it activates Gfi1), and endothelial barrier integrity through regulation of Rho GTPase-activating proteins (ARHGAP21/24), VE-cadherin junctional recruitment, and Rap1/RhoA signaling [PMID:8628307, PMID:19200805, PMID:30185409, PMID:31300405, PMID:22404772, PMID:24532287]. LYL1 assembles into multiprotein transcriptional complexes with LMO2, GATA2, and LDB1 at E-box/GATA composite elements on target promoters, interacts with CREB1 to recruit p300/CBP coactivators, and is a required component of the AETFC complex in t(8;21) AML where it recruits CARM1 to activate enhancer-driven gene expression [PMID:22792348, PMID:18160048, PMID:36215477]. LYL1 is essential for LMO2-driven thymocyte self-renewal and T-ALL initiation, establishing it as a non-redundant mediator of leukemogenic transcriptional programs [PMID:23926305, PMID:30700838].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Identification of LYL1 at a T-ALL translocation breakpoint established it as a new bHLH transcription factor family member, raising the question of its DNA-binding specificity and normal cellular function.\",\n      \"evidence\": \"Molecular cloning and sequence analysis from t(7;19) T-ALL\",\n      \"pmids\": [\"2752424\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No binding partners or DNA target specificity determined\", \"Normal tissue expression pattern not fully characterized\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstrating that LYL1 heterodimerizes with E2A proteins and binds a distinct DNA consensus sequence resolved how LYL1 achieves target gene specificity distinct from E2A homodimers.\",\n      \"evidence\": \"Yeast two-hybrid, Co-IP, PCR-assisted binding site selection\",\n      \"pmids\": [\"8628307\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous genomic targets not identified\", \"Functional consequence of DNA binding on gene expression unknown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Discovery that LYL1 physically interacts with NF-κB1 p105 and represses NF-κB-dependent transcription revealed a novel bHLH-ankyrin interaction mechanism and a potential link between LYL1 dysregulation and inflammatory/immune signaling.\",\n      \"evidence\": \"Yeast two-hybrid, in vitro binding, Co-IP, NF-κB reporter assays in T cells\",\n      \"pmids\": [\"10023675\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of LYL1-NF-κB interaction in hematopoiesis not tested in vivo\", \"Whether this interaction occurs at endogenous protein levels unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Lyl1 knockout mice established that LYL1 is required for HSC self-renewal and B-cell differentiation in vivo, moving it from an oncogene candidate to a physiological regulator of hematopoiesis; parallel promoter analysis revealed GATA-2 and Ets factor regulation of Lyl1 expression, while demonstrating that Lyl1 cannot substitute for Scl in early hematopoietic specification.\",\n      \"evidence\": \"Lyl1-KO mice with competitive repopulation, transgenic promoter analysis, ChIP, ES cell rescue\",\n      \"pmids\": [\"16514064\", \"17053063\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific transcriptional targets of LYL1 in HSCs not identified\", \"Degree of redundancy with SCL not genetically tested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identification of LYL1-CREB1 interaction and p300/CBP coactivator recruitment defined a phosphorylation-independent transcriptional activation mechanism, while overexpression studies showed LYL1 can sequester E2A and promote lymphomagenesis.\",\n      \"evidence\": \"Co-IP with domain mapping, ChIP-chip, reporter assays; mammalian two-hybrid and transgenic mouse lymphoma model\",\n      \"pmids\": [\"18160048\", \"17486074\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LYL1-CREB1 complexes operate in normal hematopoiesis vs. leukemia not distinguished\", \"Genome-wide target overlap between LYL1-E2A and LYL1-CREB1 complexes unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Conditional double-knockout of Lyl1 and Scl proved genetic redundancy for adult HSC survival, with a single Lyl1 allele sufficient for rescue, establishing LYL1 as the more potent factor in adult HSC maintenance.\",\n      \"evidence\": \"Conditional DKO mice, bone marrow repopulation, apoptosis assays\",\n      \"pmids\": [\"19200805\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for why one Lyl1 allele suffices but one Scl allele does not was not resolved\", \"Shared vs. unique chromatin targets not mapped\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Characterization of LYL1 protein turnover revealed PEST-dependent proteasomal degradation independent of MAPK-mediated Ser36 phosphorylation, while in vivo vascular studies established LYL1 as a regulator of blood vessel maturation controlling VE-cadherin, pericyte coverage, and angiopoietin-2.\",\n      \"evidence\": \"PEST mutagenesis with proteasome inhibitors; Lyl1-KO tumor implantation, Matrigel assay, LYL1 knockdown in endothelial cells\",\n      \"pmids\": [\"20844761\", \"20418284\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ubiquitin ligase targeting LYL1 not identified\", \"Transcriptional vs. post-transcriptional regulation of vascular targets not fully separated\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"A series of studies defined LYL1's multilineage functions: LYL1 occupies the ANG-2 promoter with LMO2/GATA2 in endothelial cells, maintains early T-cell progenitors via Gfi1 activation, supports erythropoiesis by regulating Bcl-xL, and co-regulates STMN1 with CREB1, collectively establishing LYL1 as a versatile bHLH factor with context-dependent target gene programs.\",\n      \"evidence\": \"ChIP, knockdown, reporter assays in endothelial cells; Lyl1-KO mouse ETP/erythroid phenotyping; ChIP-chip for STMN1 promoter\",\n      \"pmids\": [\"22792348\", \"22404772\", \"21420467\", \"23000483\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LYL1 activates different gene programs through different partner complexes (E2A vs. CREB1 vs. LMO2) in the same cell type not resolved\", \"Full genome-wide target repertoire in primary cells not mapped at this point\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Genetic epistasis demonstrated that LYL1, but not SCL, is essential for LMO2-driven thymocyte self-renewal and T-ALL, establishing a non-redundant oncogenic requirement and explaining why LYL1 is specifically co-expressed with LMO2 in ETP-ALL.\",\n      \"evidence\": \"Lmo2-Tg × Lyl1-KO vs. Scl-KO mice, serial transplantation, gene expression profiling\",\n      \"pmids\": [\"23926305\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct LYL1-LMO2 binding sites in leukemic thymocytes not mapped by ChIP-seq\", \"Whether LYL1 is sufficient or merely required for LMO2 oncogenic activity unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Mechanistic dissection of the vascular barrier phenotype showed LYL1 acts upstream of VE-cadherin and Rap1/RhoA by transcriptionally controlling ARHGAP21 and ARHGAP24, providing a molecular pathway for LYL1's endothelial function.\",\n      \"evidence\": \"LYL1 knockdown in HUVECs, Lyl1-KO mouse lung permeability (Evans blue), RhoA activity assay, immunofluorescence\",\n      \"pmids\": [\"24532287\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LYL1 directly binds ARHGAP21/24 promoters not shown by ChIP\", \"Contribution of other LYL1 vascular targets to barrier function not assessed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"ChIP-seq in erythroid cells revealed that LYL1 exclusively occupies a subset of SCL targets including the GATA1 locus, and double knockout confirmed that LYL1 maintains primitive erythropoiesis by sustaining GATA1 expression when SCL is absent.\",\n      \"evidence\": \"Conditional Scl/Lyl1 DKO, ChIP-seq in human erythroleukemia cells, transcriptomics\",\n      \"pmids\": [\"30185409\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LYL1 binds the same sites in primary erythroid progenitors vs. cell lines not confirmed\", \"Structural basis for LYL1 vs. SCL binding site preference unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Studies extended LYL1's non-redundant oncogenic role to NUP98-HOXD13-driven leukemia and confirmed redundancy with SCL in megakaryopoiesis, where both factors regulate Gata1, Fli1, and Nfe2 through shared E-box sites.\",\n      \"evidence\": \"NHD13-Tg × Lyl1-KO, serial transplantation; Pf4-Cre conditional DKO, platelet assays, ChIP-seq\",\n      \"pmids\": [\"30700838\", \"31300405\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LYL1-dependent self-renewal programs are identical across different oncogene contexts not compared\", \"Megakaryocyte-specific LYL1 ChIP-seq not performed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Disruption of LYL1's bHLH domain in yolk sac macrophage progenitors revealed a role in primitive macrophage differentiation and microglia production, expanding LYL1 function beyond definitive hematopoiesis to embryonic tissue-resident immune cell development.\",\n      \"evidence\": \"Lyl1-KO (bHLH disruption), flow cytometry, transcriptomics, immunohistochemistry in embryonic brain\",\n      \"pmids\": [\"34887504\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether residual truncated LYL1 protein retains partial activity not excluded\", \"Direct transcriptional targets in macrophage progenitors not identified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Biochemical purification of the AETFC complex in t(8;21) AML demonstrated that LYL1 is a core subunit required for complex assembly at active enhancers and recruits the coactivator CARM1 to promote AML1-ETO-dependent gene activation, providing a mechanistic basis for LYL1's role in leukemia maintenance.\",\n      \"evidence\": \"Complex purification, Co-IP, ChIP-seq, gene expression assays in Kasumi-1 cells\",\n      \"pmids\": [\"36215477\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CARM1 recruitment is specific to AETFC or shared with other LYL1 complexes unknown\", \"Therapeutic vulnerability of LYL1 within AETFC not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"New contexts for LYL1 function emerged: BHLHE40/AR-mediated upregulation of LYL1 in androgen-induced senescence and SPI1/PU.1-dependent regulation of LYL1 during endothelial-to-hematopoietic transition broadened the regulatory network governing and governed by LYL1.\",\n      \"evidence\": \"ChIP-seq, RNA-seq, Co-IP, siRNA rescue in prostate cancer cells; SPI1-KD/LYL1 rescue in human PSC-derived EHT\",\n      \"pmids\": [\"39668349\", \"39108738\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"LYL1-BHLHE40-AR complex stoichiometry and genomic targets not fully defined\", \"Whether SPI1-LYL1 axis operates in vivo during EHT not confirmed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for LYL1 vs. SCL target selectivity, the identity of the E3 ligase mediating LYL1 proteasomal turnover, genome-wide comparison of LYL1 complex composition across cell types, and whether LYL1 can be therapeutically targeted in LMO2-driven T-ALL or AML1-ETO AML.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of LYL1 or LYL1-containing complexes exists\", \"E3 ubiquitin ligase for LYL1 degradation not identified\", \"No pharmacological strategy to target LYL1 in leukemia has been tested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 1, 16]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 5, 6, 10, 11, 13, 20]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 5, 10, 20]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [5, 10, 11, 13, 16, 20]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3, 7, 16, 19]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [14, 17, 20]}\n    ],\n    \"complexes\": [\n      \"AETFC (AML1-ETO/LYL1/LMO2/LDB1/HEB/E2A/CBFβ)\",\n      \"LYL1-E2A heterodimer\",\n      \"LMO2/GATA2/LYL1/TAL1 enhancer complex\"\n    ],\n    \"partners\": [\n      \"TCF3\",\n      \"LMO2\",\n      \"LDB1\",\n      \"GATA2\",\n      \"CREB1\",\n      \"NFKB1\",\n      \"CARM1\",\n      \"BHLHE40\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}